Baseline demographics
| Details | N (in %) or mean (range) ± SD | ||
| Demographic data | n | 15 | |
| Age, years | 49.2 (19–68) ± 15.2 | ||
| Women | 8 (53.3) | ||
| Smoker | 8 (53.3) | ||
| Allergies | Nickel (n=2), NSAID (n=1), penicillin (n=1), pollinosis (n=2) | 4.0 (26.7) | |
| Systemic diseases | Asthma (n=1), CHD (n=1), cancer (n=2), diabetes (n=1), hypertension (n=2), hypercholesterinemia (n=2), RLS (n=1), hypothyroidism (n=1), anemia (n=1) | 7 (41.2) | |
| EVT | Primary flow diversion | 9 (60) | |
| Flow diversion after coiling | 5 (33.3) | ||
| Flow diversion after stent-assisted coiling | 1 (6.7) | ||
| NICE lesions | MRI characteristics | ||
| Onset after EVT (days) | 65.1 (1.0–358.0) ± 101.5 | ||
| Last follow-up (days) | 548.2 (23.0–1339.0) ± 467.0 | ||
| No. of enhancing lesions | 1 lesion | 4 (26.7) | |
| 2–5 lesions | 1 (6.7) | ||
| 6–10 lesions | 2 (13.3) | ||
| >10 lesions | 8 (53.3) | ||
| Perilesional edema | 8 (53.3) | ||
| Midline shift | 1 (6.7) | ||
| Patients with lesions outside the vascular territory of treatment | 4 (26.7) | ||
| Symptoms | |||
| Headache | 5 (33.3) | ||
| Focal neurological deficit | Hemiplegia and hemihypesthesia, neglect (n=1), impaired coordination and walking (n=1), vertigo and visually initiated seizures (n=1) | 3 (20.0) | |
| Epileptic seizures | 2 (13.3) | ||
| Cognitive impairment | 2 (13.3) | ||
| Symptom dynamics | Progression | 3 (20.0) | |
| Completely resolved | 2 (13.3) | ||
| Partially resolved | 1 (6.7) | ||
| Stable | 9 (60.0) | ||
| Treatment | |||
| None | 9 (60.0) | ||
| Glucocorticoids | Combined with ibuprofen (n=1) | 6 (40.0) | |
| Antiepileptic drugs | 2 (13.3) | ||
CHD, coronary heart disease; EVT, endovascular treatment; No., number; NSAID, non-steroidal anti-inflammatory drug; RLS, restless legs syndrome.